A Phase Ib/Ⅱ Clinical Study to Explore the Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable Hepatocellular Carcinoma
Latest Information Update: 05 Oct 2023
At a glance
- Drugs Camrelizumab (Primary) ; Lenvatinib (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- 16 Sep 2021 New trial record